Bartonella are known to be important causes of zooanthroponotic diseases. The range of human infection varies from mild lymphadenopathy and asymptomatic bacteremia to life-threatening systemic disease in immunocompromised patients. Microbiological improvements in isolation methods and PCR amplification of organism-specific DNA sequences have resulted in a dramatic increase in reports describing human patients with bartonellosis. Nevertheless, clearly and successful isolation of Bartonella spp. from bacteremic animals and human patients remains an ongoing challenge. Technology of experimental bartonellosis due to intraperitoneal introduction of biological material samples containing causative agents to laboratory animals is presented in the article. White nonlinear mice with the artificially cyclophosphamide formed immunodeficient state may be used as an experimental model for further investigation of the biological alterations responsible for angiomatosis. On the other hand, we believe that this new method will enhance the diagnostic sensitivity and specificity needed to achieve a diagnosis of bartonellosis.

Background: Actuality of study of infectious mononucleosis (ІМ) is conditioned by high infected of population by the Epstein – Barr virus (EBV), specific virus affinity to the immunocompetent cells, lifelong virus persistence in an organism and often latent process. Methods: Research on the work topic was conducted at the Department of Infectious Diseases of Kharkiv National Medical University. A total of 45 patients with IM (26 men and 19 women) who were hospitalized at the Regional Clinical Hospital in 2018–2019 years were surveyed. The vast majority of patients with IM were young people aged from 18 to 25, of whom 597 % were students. Results: The clinical picture of infectious mononucleosis caused by the Epstein–Barr virus, mainly characterized by manifestations of hepatomegaly, lymphadenopathy, intoxication syndrome and nasopharyngeal tonsillitis. The efficacy of combined use of Valacyclovir and Nuclex in complex therapy of patients with infectious mononucleosis caused by Epstein – Barr virus (EBV) was studied. The use of such therapy was found to promotes regression of clinical symptoms, contribute to normalization of indices of clinical blood tests and lead to a decrease of the number of EVB's DNA copies in the blood serum or complete elimination of virus. Conclusions: Thus, evaluation of the effectiveness of the use of valacyclovir and nuclex in the complex therapy of patients with infectious mononucleosis caused by Epstein–Barr virus, indicates a more significant regression of clinical symptoms, significantly more pronounced positive impact on the indicators of clinical blood analysis and the number of copies of EBV DNA in blood serum than in the comparison group. Obtained results allowed to substantiate the use of complex therapy of valacyclovir and nuclex in patients with IM caused by EBV.

No abstract

<p class="MsoNormal" style="margin-bottom: .0001pt; text-align: justify; text-indent: 27.0pt; line-height: normal;"><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">П</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-fareast-language: RU;" lang="RU">редставлено результати обстеження 78 </span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">х</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-fareast-language: RU;" lang="RU">вор</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">их</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-fareast-language: RU;"> <span lang="RU">на хронічн</span></span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">и</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-fareast-language: RU;" lang="RU">й гепатит С</span></em><em style="mso-bidi-font-style: normal;"></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">за допомогою</span></em><em style="mso-bidi-font-style: normal;"></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">Н</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-fareast-language: RU;" lang="RU">CV ГеноФ</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-ansi-language: UK; mso-fareast-language: RU;">іб</span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; color: black; mso-fareast-language: RU;" lang="RU">роТесту. </span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-ansi-language: UK;">На підставі аналізу вірогідності досягнення стійкої вірусологічної відповіді в залежності від генотипу </span></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-ansi-language: EN-US;" lang="EN-US">HCV</span></em><em style="mso-bidi-font-style: normal;"></em><em style="mso-bidi-font-style: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-ansi-language: UK;">та стадії фіброзу наведено рекомендації щодо тактики противірусної терапії.</span></em></p>